IVD raw materials market size was valued at $24.34 billion in 2021 and is expected to reach $34.25 billion by 2027.
Chicago, June 15, 2022 (GLOBE NEWSWIRE) -- According to Arizton’s latest research report, the IVD raw materials market is growing at a CAGR of 5.86% during the forecast period. The increasing prevalence of infectious & chronic diseases, growing awareness of early diagnosis and disease prevention, and rise in availability of advanced home care kits for cancer diagnostics are the major drivers in the market.
Molecular Point-of-Care (POC) testing has also expanded the diagnostic capabilities and overcome existing limitations at POC sites, such as critical care centers, outpatient clinics, physician offices, and other ambulatory care settings. Consequently, the total market potential of molecular POC diagnostics has increased considerably to offer tremendous growth opportunities in the future.
IVD Raw Materials Market Report Scope
Product: Antibody & Antigen, Enzymes, Proteins, Biological Buffers, and Others, Technology: Clinical Chemistry, Immunochemistry, Molecular Diagnostics, and Others, End-User: Pharma & Biotech Companies, Diagnostic Laboratories, and Others, Geography: Europe, North America, APAC, Latin America, and Middle East & Africa
Europe, North America, APAC, Latin America, and Middle East & Africa
Germany, Italy, France, UK, Spain, US, Canada, China, Japan, India, Australia, South Korea, Brazil, Mexico, Argentina, Turkey, Saudi Arabia, and South Africa
Click Here to Download the Free Sample Report
IVD medical devices have become a major sector in the field of diagnosis, leading to major advances. Such factors are accelerating the adoption of IVDs and there is a simultaneous demand for its raw materials. Furthermore, the growing trends of POC diagnostics and personalized medicine are contributing to the growth of the market. The surge in adoption of antigen-antibody testing and point-of-care diagnostics has enabled the growth of the pharma & biotech companies segment. The segment is also expected to witness the highest incremental growth of $6.35 billion during the forecast period. However, the diagnostic laboratories segment is likely to witness the highest absolute growth of 43.37% during the forecast period.
The rise in demand for diagnostics and laboratory tests attributable to the surge in the patient population due to the prevalence of chronic diseases is increasing the demand for IVD raw materials.
The global IVD raw materials market is segmented by product, technology, end-user, and geography.
In 2021, antibodies & antigens accounted for the highest share of over 36.00% in the global IVD raw materials market due to the growing demand for antigen and antibody-based tests that increased during COVID-19.
In 2021, clinical chemistry accounted for the highest share of more than 37.00% in the global IVD raw materials market with the growing number of hospitalizations and laboratory tests led by clinical chemistry.
In 2021, pharma & biotech companies accounted for the highest revenue share of over 62.00% in the global IVD raw materials market, due to the growing number of antigen-antibody testing centers, point of care diagnostics, and pharma & biotech companies.
In 2021, Europe is dominating the global IVD raw materials market with the highest share of over 34.00% due to the availability of advanced IVD devices and various developments in lab automation.
Major manufacturers of IVD raw materials are focusing on proprietary processing techniques to satisfy the raw material requirements of the IVD industry and provide IVD raw materials manufactured using off-the-shelf specifications. Also, several international players are focusing on the development of innovative products and expanding their product portfolio to ensure a sustainable presence in the market. Additionally, many vendors are constantly investing in R&D initiatives based on market trends and general health management demands. Vendors are also focusing on developing and commercializing innovative analyzers, COVID-19 PCR rapid test kits, and consumables to remain competitive and establish a significant presence in the market. For instance, Adaltis S.r.l. develops, manufactures, and markets IVD systems and reagents and offers a wide range of consumables such as tips, vials, and tubes. These vendors are actively launching innovative devices to penetrate and tap the tremendous growth potential in the market.
Explore our healthcare lifesciences profile to know more about the industry.
Click Here to Download the Free Sample Report
Read some of the top-selling reports:
Central IV Catheter Market - Global Outlook and Forecast 2020-2025
IV and Oral Iron Drugs Market - Global Outlook and Forecast 2021-2026
Hematology Diagnostics Market - Global Outlook & Forecast 2022-2027
COVID-19 Diagnostics Market - Global Outlook and Forecast 2021-2026
Arizton Advisory and Intelligence is an innovation and quality-driven firm, which offers cutting-edge research solutions to clients across the world. We excel in providing comprehensive market intelligence reports and advisory and consulting services.
We offer comprehensive market research reports on industries such as consumer goods & retail technology, automotive and mobility, smart tech, healthcare, and life sciences, industrial machinery, chemicals, and materials, IT and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.
Arizton comprises a team of exuberant and well-experienced analysts who have mastered in generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.
Click Here to Contact Us
Anyone positioning their portfolio for a recession could be making a big mistake.
“We are exiting that regime, and it’s going to be bumpy,” said the famous Fed watcher Mohamed El-Erian of the world where central banks let the money flow.
When Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) CEO Warren Buffett speaks, Wall Street and investors wisely pay close attention. While riding Buffett's coattails has been a moneymaking strategy for decades, it's equally important to take note of the stocks that the world's most successful investor and his investing team are selling or avoiding. Thus far in 2022, Warren Buffett has overseen the aggressive selling of the following five stocks.
The Bitcoin carnage continues, as the cryptocurrency breaks $20,000 to trade at its lowest level since 2020.
Investors might take some comfort in crystal-ball gazing by Bank of America, which uses history to plot the next bull market.
AMD and Nvidia have been swallowed up in the bear market, with each stock declining at least 50%. Here's how to trade them now.
Already, very early signs of slowing demand and inflation are cropping up. If the economy averts all-out disaster, then stabilizing or declining rates would spur a market rebound.
Remember TINA? She’s the one everyone was talking about for the past few years, when it came to buying stocks. ‘There is no alternative,’ they said – pointing out that the near-zero interest rate policy has pushed bond yields down to nothing, and that the housing crisis of 2008 had left investors wary of the real estate market – and stocks were the highest returning game in town. Not anymore. The Federal Reserve has just cracked the whip on rate hikes, implementing a 0.75% increase to the benchm
Retail stocks have taken a beating, but inflation, supply chain woes, and other cost concerns don't tell the full story.
A decline in earnings could be the next shoe to drop for investors. But it’s all a prelude to what may be the best buying opportunity in decades.
Since hitting their all-time closing highs, the widely followed Dow Jones Industrial Average, benchmark S&P 500, and growth stock-fueled Nasdaq Composite (NASDAQINDEX: ^IXIC) have respectively tumbled by 17%, 22%, and 33%. There's no question that the velocity and unpredictability of downward moves during a bear market can weigh on investors' psyche. This makes corrections and bear markets the opportune time to put your money to work.
Bank stocks are dirt-cheap right now, and Citi in particular looks like a bargain. Watch the Fed’s stress-test results—and Warren Buffett’s purchases—to see what might be in store.
(Bloomberg) -- Most Read from BloombergPutin Gets Unexpected Pushback From Ally Over War in UkraineChina Says It May Have Detected Signals From Alien CivilizationsSergey Brin Seeks Divorce, Joining Gates and Bezos in SplitMusk, Tesla, SpaceX Are Sued for Alleged Dogecoin Pyramid SchemeMonkeypox Testing Shows the US Learned Little From the Covid-19 PandemicA shareholder dispute over one of the world’s biggest copper and cobalt mines is heating up in the Democratic Republic of Congo, after state m
THE MONEYIST Dear Quentin, My boyfriend and I have been together seven years, and in that time I bought a house. I used my own savings and spent about $10,000 on renovations. My house is a three-bedroom family home, and the tenants cover most of my mortgage.
Hennion & Walsh CIO Kevin Mahn and Threadneedle Ventures Founder Ann Berry join Yahoo Finance Live to talk about this week's volatile market losses, which sectors investors should look into to ford recession concerns, blockchain technology across industries, and recession risks amid rising inflation and the Fed's interest rate hikes.
This year’s plunge in the stock market, unprecedented crash in the bond market, and surging inflation threaten new retirees in ways not seen before, he says. “The Jan. 1, 2022 retiree is retiring under conditions which have no certain precedent in the historical records I have used for my research,” Bengen tells MarketWatch. If the recent surge in inflation isn’t brought under control, he says, “we may witness history being made, and the first decline in the ‘safe’ withdrawal rate in more than 50 years.”
Stocks' stomach-churning start to 2022 raises big questions for the next six months. Here's what you should know.
Elon Musk is angry. Before getting to the reason for his anger, it should be noted that for more than a decade, from 2003 to almost 2013, the billionaire and Tesla pushed hard for the adoption of electric vehicles despite mockery from rivals and skepticism from financial markets and consumers. Musk and Tesla had, however, found an ear at the White House in the person of Barack Obama, newly elected in 2008.
Yahoo Finance Live takes a look at several of today's trending stocks tied to leading industry stories, including the demand destruction seen in energy markets as rising gas prices have more people opting to work from home than commuting.
(Bloomberg) -- You can look but you won’t find a stretch of futility as pervasive as the one that is landing on Wall Street.Most Read from BloombergPutin Gets Unexpected Pushback From Ally Over War in UkraineChina Says It May Have Detected Signals From Alien CivilizationsSergey Brin Seeks Divorce, Joining Gates and Bezos in SplitMusk, Tesla, SpaceX Are Sued for Alleged Dogecoin Pyramid SchemeMonkeypox Testing Shows the US Learned Little From the Covid-19 PandemicEven in the long and storied hist